Fresenius Medical Care, the world’s largest provider of dialysis products and services, today announced an important strategic step to sharpen its U.S. Care Coordination profile with the signing of a definitive agreement to divest its controlling interest in Sound Inpatient Physicians Holdings, LLC (Sound) to an investment consortium led by Summit Partners (Summit), for total transaction proceeds of $2.15 billion (EUR 1.76 billion).
As part of an ongoing commitment to support nurses dedicated to caring for patients with kidney disease, Fresenius Medical Care North America (FMCNA), the nation’s leading renal care company, and the American Nephrology Nurses Association (ANNA) announced five recipients of educational scholarships at ANNA’s 2018 National Symposium in Las Vegas.
Fresenius Medical Care North America (FMCNA), the country’s leading provider of kidney care products and services, announces the appointment of Angela McClure to the newly created role of chief experience officer (CXO).
Modern Healthcare Honors FMCNA's Saurabh Tripathi with Minority Executives to Watch in Healthcare Award
Fresenius Medical Care North America announces that Modern Healthcare recognized Saurabh Tripathi as one of 2018’s Minority Executives to Watch in Healthcare. The profiles of all the winners are featured in the February 26, 2018 print issue of Modern Healthcare and at ModernHealthcare.com/Top25Minorities.
Fresenius Medical North America (FMCNA), the nation’s leading renal care company, is making a $40,000 contribution to Kidney School, the world’s largest education program for people with chronic kidney disease.
FMCNA will serve as National Presenting Sponsor of the 2018 Kidney Walk series, the nation’s largest ongoing fundraiser to fight kidney disease. The partnership, launched at the start of National Kidney Month, sets an ambitious goal for FMCNA to contribute $750,000 this year toward kidney disease research and support.
Nephrologists, renal researchers and kidney experts from across the globe descend on Lake Buena Vista, Florida, for the 20th International Conference on Dialysis: Advances in Kidney Disease 2018, presented by the Renal Research Institute
In its second year in the program, Fresenius Kidney Care maintained its 5-Diamond status at 99 percent of its participating facilities, while increasing enrollment from 2,385 clinics in 2016 to 2,417 in 2017.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, today announced the closing of the divestment of Shiel Medical Laboratory, Inc. to Quest Diagnostics, Inc. as of December 7, 2017.
Fresenius Medical Care North America (FMCNA) employees put on their walking shoes and raised nearly $300,000, the most amount ever raised by a National Team participating in Kidney Walk, the centerpiece fundraiser of the National Kidney Foundation (NKF).
Fresenius Medical Care North America (FMCNA), the country’s leading provider of kidney care products and services, announced today the first performance year results from its End Stage Renal Disease Seamless Care Organizations (ESCOs).
Fresenius Medical Care Renal Therapies Group announced today that four abstracts on Velphoro® (sucroferric oxyhydroxide) have been accepted for presentation at the American Society of Nephrology (ASN) annual Kidney Week held Oct. 31-Nov. 5, 2017 in New Orleans. The abstracts describe the real world outcomes in serum phosphorus control and a significant reduction in pill burden achieved in hemodialysis patients who switched to Velphoro as part of their routine clinical care.